MAP2K7 and alopecia: Skin symptomatic toxicities included rash (4%-68%), alopecia (38%-66%), and photosensitivity (31%), and these symptoms tended to occur more with use of TK inhibitors, BRAF inhibitors, MEK inhibitors, and HH inhibitors.